We are pleased to announce Bray Patrick-Lake, MFS, and Edith A. Perez, MD as our keynote speakers for the PFF Summit 2019. Both women offer expertise relevant to our patient and professional audiences.
Bray Patrick-Lake, MFS
As Director of Stakeholder Engagement and Research Together program lead, Bray Patrick-Lake supports efforts to facilitate partnerships between patients, health advocacy organizations, sponsors, and investigators in Duke Clinical Research Institute’s portfolio of research activities, which includes a broad spectrum of industry sponsored trials and federally-funded research.
In 2010, Ms. Patrick-Lake founded the Patent Foramen Ovale (PFO) Research Foundation in response to the lack of definitive scientific information regarding the condition of PFO after being a patient in an aborted device clinical trial. Ms. Patrick-Lake has served as a patient representative at the FDA on a variety of advisory committees and panels, in multiple workgroups, and as a patient stakeholder or co-investigator for several research projects.
Coupled with her professional expertise and her patient perspective, Ms. Patrick-Lake will address the opportunities to engage patients as active participants in the clinical trial process, not only as study subjects but as key thought leaders in the development of clinical trials.
Edith Perez, MD
Dr. Edith Perez is an internationally recognized translational researcher and cancer specialist, Professor of Medicine at Mayo Clinic, and Director of the Mayo Clinic Breast Cancer Translational Genomics Program.
Her career experiences include leadership in academic and biopharmaceutical environments, with an added focus on philanthropic endeavors. In addition to these pursuits, Dr. Perez is the co-developer of the 26.2 National Marathon to Finish Breast Cancer (breastcancermarathon.com), with goals to raise funds for under-served women and genomics/immunologic translational cancer research.
Dr. Perez will provide a unique perspective on the role of genetic and genomic biomarkers to accelerate personalized therapies in breast cancer and its relevance to our pulmonary fibrosis community.